Kinneret Savitsky, Ph.D., CEO of BioLineRx, remarked, "2013 was a significant year for BioLineRx, with increased efforts in the specific therapeutic areas of oncology and immunology, as well as an emphasis on clinical-stage programs.
http://ift.tt/Nn6wy7
http://ift.tt/Nn6wy7
No comments:
Post a Comment